Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4 Purity >99.5% E.E >99.5%

Short Description:

Name: Boc-3-Hydroxy-1-Adamantyl-D-Glycine 

CAS: 361442-00-4

Purity: >99.5% (GC) E.E: >99.5%

Appearance: White or Off-White Crystalline Powder

Intermediate of API (CAS: 361442-04-8) 

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Boc-3-Hydroxy-1-Adamantyl-D-Glycine
Synonyms (2S)-2-((tert-Butoxycarbonyl)amino)-2-(3-Hydroxyadamantan-1-yl)acetic Acid 
CAS Number 361442-00-4
CAT Number RF-PI1989
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C17H27NO5
Molecular Weight 325.40
Boiling Point 497.3±20.0℃
Density 1.296
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Crystalline Powder
Water (K.F) <0.50%
Loss on Drying <1.00%
Residue on Ignition <0.50%
Single Impurity <0.50%
Total Impurities <0.50%
E.E >99.5% 
Purity >99.5% 
Infrared Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Boc-3-Hydroxy-1-Adamantyl-D-Glycine (CAS: 361442-00-4) is an intermediate of API (CAS: 361442-04-8). API (CAS: 361442-04-8) is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. It is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is not for treating type 1 diabetes. It is sometimes used in combination with other diabetes medications. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor.

  • Write your message here and send it to us